HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLOUDBREAK-B

1.190

0.000

Volume:- -

Turnover:- -

Market Cap:1.10B

PE:-11.55

High:1.190

Open:1.190

Low:1.190

Close:1.190

52wk High:9.580

52wk Low:0.900

Shares:925.00M

HK Float Shares:925.00M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(LYR):-0.103

ROE:--

ROA:-190.68%

PB:3.34

PE(LYR):-11.55

PS:521.75

Loading ...

Overview Company News Filings

CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358

Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs

Cloudbreak Pharma submits FDA IND for dry eye drug candidate CBT-358

Cloudbreak Pharma Inc - Submits Ind Application for Cbt-358 to FDA

THOMSON REUTERS

Cloudbreak Pharma Postpones 2026 Annual General Meeting to 26 June

Bulletin Express

Cloudbreak Pharma to present at Stifel Virtual Ophthalmology Forum

CLOUDBREAK-B Receives FDA Clearance for Safety Review of CBT-199

BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May Proceed

Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed

THOMSON REUTERS

Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain

Bulletin Express

Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return

THOMSON REUTERS

Cloudbreak Pharma redeems fund after use-of-proceeds non-compliance issue

Cloudbreak Pharma to present MKI platform at Eyecelerator @ ARVO 2026

Here's Why We're Watching Cloudbreak Pharma's (HKG:2592) Cash Burn Situation

Simply Wall St.

CLOUDBREAK-B Allocates 1.785 Million Shares

Cloudbreak Pharma files HKEX next-day return for 1,785,000 shares at HKD 0

Cloudbreak Pharma publishes 2025 annual report

Cloudbreak Pharma Releases First ESG Report: Sets 2027 Resource-Efficiency Targets and Reports 2025 GHG Emissions of 533.06 tCO₂e

Bulletin Express

CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million

Cloudbreak Pharma FY25 net loss narrows to US$ 68 million; revenue posts no revenue

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/stock/02592/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"02592","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","market":"HK","secType":"STK","nameCN":"CLOUDBREAK-B","latestPrice":1.19,"timestamp":1789348803512,"preClose":1.19,"halted":3,"volume":0,"delay":0,"changeRate":0,"floatShares":925000000,"shares":925000000,"eps":-0.103023,"marketStatus":"Halted","change":0,"latestTime":"09-14 11:52:43","open":1.19,"high":1.19,"low":1.19,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":0,"etf":0,"ttmEps":-1.024,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1789358400000},"marketStatusCode":2,"adr":0,"listingDate":1751472000000,"exchange":"SEHK","adjPreClose":1.19,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"volumeRatio":0,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02592\",,,,,undefined,":{"symbol":"02592","floatShares":925000000,"roa":"-190.68%","roe":"--","lyrEps":-0.103023,"shares":925000000,"dividePrice":0,"high":1.19,"amplitude":0,"preClose":1.19,"low":1.19,"week52Low":0.9,"pbRate":"3.34","psRate":"521.75","week52High":9.58,"institutionHeld":0,"latestPrice":1.19,"eps":-0.103023,"divideRate":0,"volume":0,"delay":0,"ttmEps":-1.024,"open":1.19,"prevYearClose":5.2,"prevWeekClose":1.19,"prevMonthClose":1.145,"prevQuarterClose":1.56,"fiveDayClose":1.185,"twentyDayClose":1.17,"sixtyDayClose":1.17},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02592\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-30","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774834200000,"name":null,"time":"","dateTimestamp":1774800000000,"actualEps":null},{"date":"2025-08-29","symbol":"02592","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02592\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02592\",market:\"HK\",delay:false,,,undefined,":{},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02592\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02592","date":"2026-09-11","current":-1.162109,"percent":0.97619,"low":-24.505522,"twenty":-11.839754,"median":-5.586446,"eighty":-2.054785,"high":-1.021022,"avg":-6.532259,"sd":4.944909,"marketCap":1005033411},"quantilePoints":[{"date":"2025-07-04","current":-6.317277,"twenty":-6.610502,"median":-6.500542,"eighty":-6.390583,"marketCap":4915912241},{"date":"2025-07-11","current":-6.166376,"twenty":-6.470405,"median":-6.317277,"eighty":-6.263403,"marketCap":4798467239},{"date":"2025-07-18","current":-6.350904,"twenty":-6.498689,"median":-6.350281,"eighty":-6.263403,"marketCap":4941079027},{"date":"2025-07-25","current":-6.080141,"twenty":-6.48004,"median":-6.306537,"eighty":-6.134066,"marketCap":4731355809},{"date":"2025-08-01","current":-5.497985,"twenty":-6.418895,"median":-6.177156,"eighty":-6.011186,"marketCap":4278353657},{"date":"2025-08-08","current":-5.49809,"twenty":-6.350655,"median":-6.13405,"eighty":-5.65539,"marketCap":4278353657},{"date":"2025-08-15","current":-5.725306,"twenty":-6.343182,"median":-6.058573,"eighty":-5.554248,"marketCap":4446132232},{"date":"2025-08-22","current":-5.53457,"twenty":-6.315129,"median":-6.004685,"eighty":-5.554248,"marketCap":4286742586},{"date":"2025-08-29","current":-5.503941,"twenty":-6.295753,"median":-5.870846,"eighty":-5.538055,"marketCap":4253186871},{"date":"2025-09-05","current":-5.413205,"twenty":-6.239682,"median":-5.742284,"eighty":-5.49926,"marketCap":4186075441},{"date":"2025-09-12","current":-12.640894,"twenty":-6.350655,"median":-5.870846,"eighty":-5.508123,"marketCap":4118964011},{"date":"2025-09-19","current":-12.711577,"twenty":-6.612702,"median":-6.004685,"eighty":-5.525012,"marketCap":4135741868},{"date":"2025-09-26","current":-11.804503,"twenty":-12.358821,"median":-6.058573,"eighty":-5.527436,"marketCap":3842129362},{"date":"2025-10-03","current":-6.439136,"twenty":-12.191113,"median":-6.134046,"eighty":-5.53457,"marketCap":2096453591},{"date":"2025-10-10","current":-5.988337,"twenty":-11.881825,"median":-6.134089,"eighty":-5.548508,"marketCap":1949083838},{"date":"2025-10-17","current":-12.3346,"twenty":-12.21981,"median":-6.187936,"eighty":-5.561014,"marketCap":4009907937},{"date":"2025-10-24","current":-11.844495,"twenty":-12.25273,"median":-6.279578,"eighty":-5.580054,"marketCap":3850518291},{"date":"2025-10-31","current":-12.15705,"twenty":-12.335851,"median":-6.333467,"eighty":-5.585568,"marketCap":3951185436},{"date":"2025-11-07","current":-11.838569,"twenty":-12.273198,"median":-6.424535,"eighty":-5.601607,"marketCap":3850518291},{"date":"2025-11-14","current":-11.510378,"twenty":-12.207573,"median":-6.465107,"eighty":-5.621104,"marketCap":3741462218},{"date":"2025-11-21","current":-12.23865,"twenty":-12.234818,"median":-6.500592,"eighty":-5.630174,"marketCap":3984741151},{"date":"2025-11-28","current":-21.343443,"twenty":-12.412307,"median":-6.613869,"eighty":-5.677994,"marketCap":6946032996},{"date":"2025-12-05","current":-20.614529,"twenty":-12.626633,"median":-6.790202,"eighty":-5.718633,"marketCap":6711142992},{"date":"2025-12-12","current":-17.961539,"twenty":-12.716498,"median":-11.142834,"eighty":-5.735493,"marketCap":5847083331},{"date":"2025-12-19","current":-14.819321,"twenty":-12.837409,"median":-11.27102,"eighty":-5.75741,"marketCap":4823634025},{"date":"2025-12-24","current":-14.055026,"twenty":-12.984934,"median":-11.600706,"eighty":-5.767869,"marketCap":4571966163},{"date":"2026-01-02","current":-11.620216,"twenty":-12.995771,"median":-11.729724,"eighty":-5.769371,"marketCap":3783406861},{"date":"2026-01-09","current":-7.540769,"twenty":-12.961935,"median":-11.510378,"eighty":-5.972321,"marketCap":2457956120},{"date":"2026-01-16","current":-8.049692,"twenty":-12.941587,"median":-11.169175,"eighty":-5.988337,"marketCap":2625734695},{"date":"2026-01-23","current":-6.609576,"twenty":-12.863288,"median":-10.620058,"eighty":-5.996682,"marketCap":2155954686},{"date":"2026-01-30","current":-6.294491,"twenty":-12.820156,"median":-9.452561,"eighty":-6.004685,"marketCap":2055287541},{"date":"2026-02-06","current":-5.800172,"twenty":-12.797534,"median":-8.075865,"eighty":-6.004685,"marketCap":1895897895},{"date":"2026-02-13","current":-5.772062,"twenty":-12.788929,"median":-7.957902,"eighty":-5.976779,"marketCap":1887508966},{"date":"2026-02-20","current":-5.722622,"twenty":-12.762909,"median":-7.89408,"eighty":-5.899654,"marketCap":1870731109},{"date":"2026-02-27","current":-5.716309,"twenty":-12.718958,"median":-7.540769,"eighty":-5.819712,"marketCap":1870731109},{"date":"2026-03-06","current":-5.592845,"twenty":-12.7039,"median":-6.802294,"eighty":-5.77076,"marketCap":1828786465},{"date":"2026-03-13","current":-5.252211,"twenty":-12.674344,"median":-6.763399,"eighty":-5.752368,"marketCap":1719730391},{"date":"2026-03-20","current":-4.787506,"twenty":-12.644727,"median":-6.625153,"eighty":-5.711698,"marketCap":1568729674},{"date":"2026-03-27","current":-4.279308,"twenty":-12.631386,"median":-6.530805,"eighty":-5.600393,"marketCap":1400951099},{"date":"2026-04-02","current":-4.3756,"twenty":-12.611231,"median":-6.512878,"eighty":-5.567465,"marketCap":1434506814},{"date":"2026-04-10","current":-4.248889,"twenty":-12.593551,"median":-6.499576,"eighty":-5.532786,"marketCap":1392562170},{"date":"2026-04-17","current":-3.434267,"twenty":-12.529717,"median":-6.439136,"eighty":-5.502771,"marketCap":1124116451},{"date":"2026-04-24","current":-3.028108,"twenty":-12.499065,"median":-6.412742,"eighty":-5.465751,"marketCap":1604675194},{"date":"2026-04-30","current":-2.35827,"twenty":-12.455796,"median":-6.350281,"eighty":-5.436669,"marketCap":1249957520},{"date":"2026-05-08","current":-2.422963,"twenty":-12.412307,"median":-6.306537,"eighty":-5.348441,"marketCap":1283740155},{"date":"2026-05-15","current":-2.215232,"twenty":-12.362936,"median":-6.237324,"eighty":-5.224545,"marketCap":1173946589},{"date":"2026-05-22","current":-2.103037,"twenty":-12.335851,"median":-6.187936,"eighty":-5.079251,"marketCap":1114826977},{"date":"2026-05-29","current":-2.055189,"twenty":-12.29622,"median":-6.159956,"eighty":-4.693687,"marketCap":1089490000},{"date":"2026-06-05","current":-1.943602,"twenty":-12.236095,"median":-6.134636,"eighty":-4.452767,"marketCap":1030370388},{"date":"2026-06-12","current":-2.070618,"twenty":-12.215803,"median":-6.134042,"eighty":-4.302022,"marketCap":1097935659},{"date":"2026-06-18","current":-1.863414,"twenty":-12.1843,"median":-6.080141,"eighty":-4.208883,"marketCap":988142093},{"date":"2026-06-26","current":-1.607919,"twenty":-12.150518,"median":-6.004708,"eighty":-3.379693,"marketCap":853011550},{"date":"2026-07-03","current":-2.053171,"twenty":-12.124388,"median":-5.992509,"eighty":-2.739542,"marketCap":1089490000},{"date":"2026-07-10","current":-2.134398,"twenty":-12.109822,"median":-5.972321,"eighty":-2.532616,"marketCap":1131718295},{"date":"2026-07-17","current":-2.101828,"twenty":-11.973906,"median":-5.886479,"eighty":-2.422963,"marketCap":1114826977},{"date":"2026-07-24","current":-2.069578,"twenty":-11.968515,"median":-5.84391,"eighty":-2.309668,"marketCap":1097935659},{"date":"2026-07-31","current":-1.862057,"twenty":-11.947093,"median":-5.798666,"eighty":-2.247923,"marketCap":988142093},{"date":"2026-08-07","current":-1.925288,"twenty":-11.910048,"median":-5.770977,"eighty":-2.212119,"marketCap":1021924729},{"date":"2026-08-14","current":-1.869116,"twenty":-11.882099,"median":-5.767494,"eighty":-2.165101,"marketCap":992364923},{"date":"2026-08-21","current":-1.909914,"twenty":-11.871403,"median":-5.723964,"eighty":-2.134253,"marketCap":1013479070},{"date":"2026-08-28","current":-1.839188,"twenty":-11.868929,"median":-5.708624,"eighty":-2.114609,"marketCap":975473605},{"date":"2026-09-04","current":-1.052314,"twenty":-11.849329,"median":-5.61954,"eighty":-2.086117,"marketCap":996587752},{"date":"2026-09-11","current":-1.061097,"twenty":-11.839754,"median":-5.586446,"eighty":-2.054785,"marketCap":1005033411}],"updateTime":1789357963757},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02592\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1100019197","title":"CLOUDBREAK-B (02592) Submits Investigational New Drug Application for CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=1100019197","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1100019197?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:40","pubTimestamp":1779460828,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on May 21, 2026, the group submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for CBT-358. CBT-358 is the most...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637348801","title":"Cloudbreak Pharma reallocates HK$103.6 million IPO proceeds to expand dry-eye R&D programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2637348801","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637348801?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:37","pubTimestamp":1779460672,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma outlined a revised funding plan for the HK$524.6 million in net IPO proceeds, shifting HK$103.6 million away from CBT-009 following the decision to withdraw its current China IND application for a possible phase 3 trial.Reallocated funds target faster clinical and regulatory work on CBT-001 and CBT-004, accelerated development of SFA+ pipeline assets including CBT-358 and CBT-277, and higher general corporate funding.Under the revised plan, total allocations rise to HK$359.2 million for CBT-001 and CBT-004 programs, HK$84.1 million for CBT-009, CBT-358 and CBT-277, HK$28.8 million for manufacturing and commercialization, and HK$52.5 million for working capital.Unutilized proceeds stood at HK$312.6 million, with spending to be governed by tighter board-level budgeting and authorization controls.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL7HxKHn:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310073","title":"Cloudbreak Pharma submits FDA IND for dry eye drug candidate CBT-358","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310073","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310073?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:33","pubTimestamp":1779460438,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma submitted a US FDA investigational new drug application for CBT-358 on May 21, 2026.The filing starts the FDA review needed to clear the candidate into clinical trials for dry eye disease.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange  , on May 22, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nNDL1f1jVW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637310026","title":"Cloudbreak Pharma Inc - Submits Ind Application for Cbt-358 to FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2637310026","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637310026?lang=en_us&edition=fundamental","pubTime":"2026-05-22 22:33","pubTimestamp":1779460436,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260522:nFWN41Z0NN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1143070511","title":"Cloudbreak Pharma Postpones 2026 Annual General Meeting to 26 June","url":"https://stock-news.laohu8.com/highlight/detail?id=1143070511","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143070511?lang=en_us&edition=fundamental","pubTime":"2026-05-20 16:43","pubTimestamp":1779266633,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (HKEX: 02592, “Cloudbreak-B”) has rescheduled its forthcoming Annual General Meeting, originally set for 29 May 2026, to 26 June 2026. The Board cited the need for additional...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634038216","title":"Cloudbreak Pharma to present at Stifel Virtual Ophthalmology Forum","url":"https://stock-news.laohu8.com/highlight/detail?id=2634038216","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634038216?lang=en_us&edition=fundamental","pubTime":"2026-05-12 20:02","pubTimestamp":1778587333,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma will participate in Stifel 2026 Virtual Ophthalmology Forum on May 26, 2026.Virtual fireside chat scheduled for 4:00 p.m. ET.Virtual one-on-one meetings with institutional investors planned throughout day.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260512:nNDLbnX8kN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","LU2210150020.SGD","LU0314104364.USD","NDAQ","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4112","BK4127","IE00BKPKM429.USD","LU2095319765.USD","BK1161","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","BK4585","IE00BN0W2V16.EUR","IE00B64PRP62.GBP","SG9999014039.USD","SF","SG9999014005.SGD","IE00BN0W2W23.USD","LU2210149790.SGD","SG9999014021.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1105385618","title":"CLOUDBREAK-B Receives FDA Clearance for Safety Review of CBT-199","url":"https://stock-news.laohu8.com/highlight/detail?id=1105385618","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1105385618?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:50","pubTimestamp":1777539018,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that its wholly-owned subsidiary, ADS Therapeutics LLC, incorporated in Delaware, USA, has completed the review period for the Investigational New Drug (IND)...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CBT","BK4090","02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631865376","title":"BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May Proceed","url":"https://stock-news.laohu8.com/highlight/detail?id=2631865376","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631865376?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:39","pubTimestamp":1777538344,"startTime":"0","endTime":"0","summary":"BRIEF-Cloudbreak Pharma Says FDA Completes Safety Review Of CBT-199 IND Application; Clinical Investigation May ProceedApril 30  - Cloudbreak Pharma Inc 2592.HK:FDA COMPLETES SAFETY REVIEW OF CBT-199 IND APPLICATION; CLINICAL INVESTIGATION MAY PROCEEDFurther company coverage: 2592.HK ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631668639","title":"Cloudbreak Pharma Inc - FDA Completes Safety Review of Cbt-199 Ind Application; Clinical Investigation May Proceed","url":"https://stock-news.laohu8.com/highlight/detail?id=2631668639","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631668639?lang=en_us&edition=fundamental","pubTime":"2026-04-30 16:37","pubTimestamp":1777538249,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260430:nFWN41D0P6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136105724","title":"Cloudbreak Pharma Completes HK$48.00 Million Fund Redemption, Booking HK$0.88 Million Gain","url":"https://stock-news.laohu8.com/highlight/detail?id=1136105724","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136105724?lang=en_us&edition=fundamental","pubTime":"2026-04-22 21:03","pubTimestamp":1776862995,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma Inc. (CLOUDBREAK-B) has fully redeemed its investment in an offshore fund, receiving HK$48.00 million in proceeds and realizing a HK$0.88 million gain, equivalent to an annualised...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049285","title":"Cloudbreak Pharma Inc - Redeems Fund in Full, Receives HK$48.0 Mln, Records HK$0.88 Mln Gain, 2.53% Annualised Return","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049285","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049285?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:42","pubTimestamp":1776861766,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nFWN415089:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629049287","title":"Cloudbreak Pharma redeems fund after use-of-proceeds non-compliance issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2629049287","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629049287?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:42","pubTimestamp":1776861765,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma redeemed an investment fund in full to address a compliance issue tied to a temporary deviation from its IPO use-of-proceeds plan.Cloudbreak booked a gain of about HK$880,000 on the exit, implying an annualized return of about 2.5%.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL6lW4r0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629466160","title":"Cloudbreak Pharma to present MKI platform at Eyecelerator @ ARVO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2629466160","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629466160?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:09","pubTimestamp":1776859749,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma will present its multi-kinase inhibition platform at Eyecelerator @ ARVO 2026 on May 1, 2026, in Denver.Presentation, titled “Multi-Kinase Inhibition: A New Focus for the Anterior Segment,” is scheduled for 1:36-1:41 pm MDT.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDLb99qsv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","NDAQ","LU2095319765.USD","SG9999014005.SGD","SG9999014013.SGD","IE00BN0W2T93.GBP","BK4112","IE00BGHQF748.EUR","LU2210150020.SGD","IE00B3QW5Z07.USD","IE00BN0W2W23.USD","BK1161","LU2210149790.SGD","IE00BKPKM429.USD","02592","SG9999014021.USD","BK4585","IE00B64PRP62.GBP","SG9999014039.USD","LU0314104364.USD","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628476835","title":"Here's Why We're Watching Cloudbreak Pharma's (HKG:2592) Cash Burn Situation","url":"https://stock-news.laohu8.com/highlight/detail?id=2628476835","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628476835?lang=en_us&edition=fundamental","pubTime":"2026-04-19 08:11","pubTimestamp":1776557481,"startTime":"0","endTime":"0","summary":"Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/heres-why-were-watching-cloudbreak-pharmas-hkg2592-cash-burn","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2592/cloudbreak-pharma-shares/news/heres-why-were-watching-cloudbreak-pharmas-hkg2592-cash-burn","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1144898650","title":"CLOUDBREAK-B Allocates 1.785 Million Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1144898650","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1144898650?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:38","pubTimestamp":1775558289,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced that on April 3, 2026, the company allotted and issued 1.785 million shares under the 2023 Equity Incentive Plan.","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625931527","title":"Cloudbreak Pharma files HKEX next-day return for 1,785,000 shares at HKD 0","url":"https://stock-news.laohu8.com/highlight/detail?id=2625931527","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625931527?lang=en_us&edition=fundamental","pubTime":"2026-04-07 18:09","pubTimestamp":1775556581,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma filed a next day disclosure return reporting issuance of 1,785,000 new ordinary shares on April 3, 2026 under its 2023 equity incentive scheme.Issued shares outstanding rose to 851,907,081 from 850,122,081.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on April 07, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260407:nNDLbcC9tC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624595715","title":"Cloudbreak Pharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2624595715","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624595715?lang=en_us&edition=fundamental","pubTime":"2026-04-01 06:32","pubTimestamp":1774996355,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma annual report for 2025 highlighted progress toward a commercial-stage transition following July 2025 Hong Kong listing that raised net proceeds of about HK$500 million.Lead asset CBT-001 for pterygium completed Phase 3 global enrollment in May 2025 with 660 patients, with top-line data expected in 2026.Pipeline focus broadened with CBT-199 for presbyopia entering clinical stage in December 2025, with FDA IND review ending without a clinical hold.CBT-009 pediatric myopia program advanced with FDA IND filing, with China Phase 3 plans reset following voluntary withdrawal of PRC IND to manage development risk.Management reiterated target for first product launch in 2027, with business development aimed at adding 1-2 new regional licensing deals in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purpose","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDLbtWjV5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127781440","title":"Cloudbreak Pharma Releases First ESG Report: Sets 2027 Resource-Efficiency Targets and Reports 2025 GHG Emissions of 533.06 tCO₂e","url":"https://stock-news.laohu8.com/highlight/detail?id=1127781440","media":"Bulletin Express","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127781440?lang=en_us&edition=fundamental","pubTime":"2026-03-31 23:04","pubTimestamp":1774969470,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma published its inaugural Environmental, Social and Governance Report, detailing 2025 performance metrics, governance arrangements and mid-term sustainability goals. Key takeaways...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1134093030","title":"CLOUDBREAK-B Reports Narrowed Annual Loss of $67.66 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=1134093030","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134093030?lang=en_us&edition=fundamental","pubTime":"2026-03-31 01:44","pubTimestamp":1774892659,"startTime":"0","endTime":"0","summary":"CLOUDBREAK-B (02592) announced its annual results for the period ending December 31, 2025. The group's research and development expenses reached $66.802 million, representing an increase of 76.04%...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623534121","title":"Cloudbreak Pharma FY25 net loss narrows to US$ 68 million; revenue posts no revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2623534121","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623534121?lang=en_us&edition=fundamental","pubTime":"2026-03-30 23:08","pubTimestamp":1774883325,"startTime":"0","endTime":"0","summary":"Cloudbreak Pharma posted a net loss of US$ 68 million for fiscal 2025, narrowing from the prior year.Revenue fell to no revenue from US$ 10 million a year earlier.Operating loss widened to US$ 107 million, pressured by higher general and administrative spending and research and development expenses.Cash and cash equivalents rose to US$ 40 million, while total assets climbed to US$ 67 million.Phase 3 recruitment for lead candidate CBT-001 completed with 660 patients, with initial efficacy and safety data expected later in 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cloudbreak Pharma Inc. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260330:nNDL6xLhFL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02592","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":3,"totalSize":72,"code":"91000000","status":"200"}]}}